BeOne Medicines director disposes ADS for tax withholding

BeOne Medicines Ltd. director Yi Qingqing reported a small share disposition linked to equity compensation.

Rhea-AI Filing Summary

BeOne Medicines Ltd. director Yi Qingqing reported a small share disposition linked to equity compensation. On June 1, 2026, Yi disposed of 235 American Depositary Shares of BeOne Medicines at $279.13 per ADS. According to the disclosure, this sale was carried out under a mandatory tax withholding provision in Yi’s restricted share unit (RSU) agreement in connection with RSU vesting, rather than as a discretionary open-market trade. Following the transactions reported, Yi holds 24,271 Ordinary Shares directly, reflecting a continuing equity stake in the company.

Insider Trade Summary

Net Seller: 235 shares

Net Sell 2 txns

Insider Yi Qingqing

Role Director

Sold 235 shs ($66K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	235	$279.13	$66K
holding	Ordinary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 0 shares (Direct); Ordinary Shares — 24,271 shares (Direct)

Footnotes (2)

1. F1. Each American Depositary Share represents 13 Ordinary Shares.
2. F2. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of restricted share units ("RSUs") previously granted to the Reporting Person. The RSUs shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

Key Figures

ADS sold: 235 ADS Sale price per ADS: $279.13 per ADS Ordinary Shares held after: 24,271 Ordinary Shares +2 more

5 metrics

ADS sold 235 ADS Disposition on June 1, 2026

Sale price per ADS $279.13 per ADS Open-market sale classification

Ordinary Shares held after 24,271 Ordinary Shares Direct ownership following reported transactions

ADS-to-Ordinary ratio 1 ADS = 13 Ordinary Shares Relationship between American Depositary Shares and Ordinary Shares

Net buy/sell shares -235 shares Net share change across reported transactions

Key Terms

American Depositary Shares, restricted share units, mandatory tax withholding provision, change in control, +1 more

5 terms

American Depositary Shares financial

"Each American Depositary Share represents 13 Ordinary Shares."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted share units financial

"The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

mandatory tax withholding provision financial

"The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement"

change in control financial

"Unvested securities are subject to accelerated vesting upon a change in control or certain termination events."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

accelerated vesting financial

"Unvested securities are subject to accelerated vesting upon a change in control or certain termination events."

A contract feature that makes stock awards, options, or restricted shares become owned or exercisable earlier than the original schedule. It shortens or cancels the waiting period so recipients can sell, transfer, or exercise their equity sooner — think of a timed lock that is unlocked ahead of schedule. It matters to investors because it changes when shares enter the market, who controls them, and how much dilution or ownership concentration happens.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BeOne Medicines (ONC) director Yi Qingqing report?

Director Yi Qingqing reported disposing of 235 American Depositary Shares of BeOne Medicines Ltd. at $279.13 per ADS. The filing describes this as a mandatory tax-related sale connected to the vesting of previously granted restricted share units.

Was Yi Qingqing’s BeOne Medicines (ONC) share sale a discretionary open-market trade?

The filing states the ADS sale was executed under a mandatory tax withholding provision in Yi’s RSU award agreement. This means the disposition was to cover tax obligations on vesting, not a voluntary decision to reduce exposure through a typical open-market sale.

How many BeOne Medicines (ONC) ADS did the director dispose of and at what price?

Yi Qingqing disposed of 235 American Depositary Shares of BeOne Medicines Ltd. at a reported price of $279.13 per ADS. The transaction is classified as a sale, but the accompanying footnote highlights its role in satisfying tax withholding requirements.

What BeOne Medicines (ONC) holdings does Yi Qingqing report after this Form 4 filing?

After the reported transactions, Yi lists 24,271 Ordinary Shares of BeOne Medicines Ltd. held directly. The Form 4 shows zero ADS remaining, but the Ordinary Share position indicates an ongoing ownership interest in the company’s equity.

How are BeOne Medicines (ONC) American Depositary Shares related to Ordinary Shares?

The disclosure notes that each American Depositary Share represents 13 Ordinary Shares of BeOne Medicines Ltd.. This ratio helps investors understand how ADS listed for trading correspond to the underlying Ordinary Shares issued by the company in its home jurisdiction.

What vesting terms apply to Yi Qingqing’s BeOne Medicines (ONC) RSUs?

Yi’s restricted share units become fully vested on the earlier of the first anniversary of the grant date or the next annual general meeting. Vesting stops if Yi ceases serving as a director, with provisions for accelerated vesting upon a change in control or certain termination events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yi Qingqing

(Last) (First) (Middle)

OFFICE #122, WINDWARD 3 BUILDING

REGATTA OFFICE PARK

(Street)

GEORGETOWN, GRAND CAYMAN KY1 1103

(City) (State) (Zip)

CAYMAN ISLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								24,271	D
American Depositary Shares(1)	06/01/2026		S(2)		235	D	$279.13	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of restricted share units ("RSUs") previously granted to the Reporting Person. The RSUs shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

	s/ Qingqing Yi	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)